nach oben

Erschienen in:

01.09.2011 | Original Research Paper

GC/MS-based profiling of amino acids and TCA cycle-related molecules in ulcerative colitis

verfasst von: Makoto Ooi, Shin Nishiumi, Tomoo Yoshie, Yuuki Shiomi, Michitaka Kohashi, Ken Fukunaga, Shiro Nakamura, Takayuki Matsumoto, Naoya Hatano, Masakazu Shinohara, Yasuhiro Irino, Tadaomi Takenawa, Takeshi Azuma, Masaru Yoshida

Erschienen in: Inflammation Research | Ausgabe 9/2011

Einloggen, um Zugang zu erhalten

Abstract

Objective

The roles that amino acids play in immunity and inflammation are well defined, and the relationship between inflammatory bowel disease (IBD) and certain amino acids has recently attracted attention. In this study, the levels of amino acids and trichloroacetic acid (TCA) cycle-related molecules in the colonic tissues and sera of patients with ulcerative colitis (UC) were profiled by gas chromatography/mass spectrometry (GC/MS), with the aim of evaluating whether the clinical state induced by UC leads to variations in the amino acid profile.

Materials and methods

Colonic biopsy samples from 22 UC patients were used, as well as serum samples from UC patients (n = 13), Crohn’s disease (CD) patients (n = 21), and healthy volunteers (n = 17).

Results

In the GC/MS-based profiling of amino acids and TCA cycle-related molecules, lower levels of 16 amino acids and 5 TCA cycle-related molecules were observed in the colonic lesion tissues of the UC patients, and the serum profiles of amino acids and TCA cycle-related molecules of the UC patients were different from those of the CD patients and healthy volunteers.

Conclusions

Our study raises the possibility that GC/MS-based profiling of amino acids and TCA cycle-related molecules is a useful early diagnostic tool for UC.

Bonen DK, Cho JH. The genetics of inflammatory bowel disease. Gastroenterology. 2003;124:521–36.PubMedCrossRef

Katz JA, Itoh J, Fiocchi C. Pathogenesis of inflammatory bowel disease. Curr Opin Gastroenterol. 1999;15:291–7.PubMedCrossRef

Young Y, Abreu MT. Advances in the pathogenesis of inflammatory bowel disease. Curr Gastroenterol. 2006;8:470–7.CrossRef

Lochs H, Dejong C, Hammarqvist F, Hebuterne X, Leon-Sanz M, Schütz T, van Gemert W, van Gossum A, Valentini L, Lübke H, Bischoff S, Engelmann N, Thul P. ESPEN guidelines on enteral nutrition: gastroenterology. Clin Nutr. 2006;25:260–74.PubMedCrossRef

Homan M, Baldassano RN, Mamula P. Managing complicated Crohn’s disease in children and adolescents. Nat Clin Pract Gastroenterol Hepatol. 2005;2:572–9.PubMedCrossRef

Johnson T, Macdonald S, Hill SM, Thomas A, Murphy MS. Treatment of active Crohn’s disease in children using partial enteral nutrition with liquid formula: a randomised controlled trial. Gut. 2006;55:356–61.PubMedCrossRef

Yamamoto T, Nakahigashi M, Saniabadi AR. Review article: diet and inflammatory bowel disease-epidemiology and treatment. Aliment Pharmacol Ther. 2009;30:99–112.PubMedCrossRef

Matsui T, Sakurai T, Yao T. Nutritional therapy for Crohn’s disease in Japan. J Gastroenterol. 2005;40:25–31.PubMedCrossRef

Ameho CK, Adjei AA, Harrison EK, Takeshita K, Morioka T, Arakaki Y, Ito E, Suzuki I, Kulkarni AD, Kawajiri A, Yamamoto S. Prophylactic effect of dietary glutamine supplementation on interleukin 8 and tumor necrosis factor alpha production in trinitrobenzene sulphonic acid induced colitis. Gut. 1997;41:487–93.PubMedCrossRef

10.

Israeli E, Berenshtein E, Wengrower D, Aptekar L, Kohen R, Zajicek G, Goldin E. Prophylactic administration of topical glutamine enhances the capability of the rat colon to resist inflammatory damage. Dig Dis Sci. 2004;49:1705–12.PubMedCrossRef

11.

Giriş M, Erbil Y, Doğru-Abbasoğlu S, Yanik BT, Aliş H, Olgaç V, Toker GA. The effect of heme oxygenase-1 induction by glutamine on TNBS-induced colitis. The effect of glutamine on TNBS colitis. Int J Colorectal Dis. 2007;22:591–9.PubMedCrossRef

12.

Vicario M, Amat C, Rivero M, Moretó M, Pelegrí C. Dietary glutamine affects mucosal functions in rats with mild DSS-induced colitis. J Nutr. 2007;137:1931–7.PubMed

13.

Arndt H, Kullmann F, Reuss F, Schölmerich J, Palitzsch KD. Glutamine attenuates leukocyte endothelial cell adhesion in indomethacin-induced intestinal inflammation in the rat. JPEN J Parenter Enteral Nutr. 1999;23:12–8.PubMedCrossRef

14.

Basivireddy J, Jakob M, Balasubramanian KA. Oral glutamine attenuates indomethacin-induced small intestinal damage. Clin Sci. 2004;107:281–9.PubMedCrossRef

15.

Fillmann H, Kretzmann NA, San-Miguel B, Llesuy S, Marroni N, González-Gallego J, Tuñón MJ. Glutamine inhibits over-expression of pro-inflammatory genes and down-regulates the nuclear factor kappaB pathway in an experimental model of colitis in the rat. Toxicology. 2007;236:217–26.PubMedCrossRef

16.

Tsune I, Ikejima K, Hirose M, Yoshikawa M, Enomoto N, Takei Y, Sato N. Dietary glycine prevents chemical-induced experimental colitis in the rat. Gastroenterology. 2003;125:775–85.PubMedCrossRef

17.

Andou A, Hisamatsu T, Okamoto S, Chinen H, Kamada N, Kobayashi T, Hashimoto M, Okutsu T, Shimbo K, Takeda T, Matsumoto H, Sato A, Ohtsu H, Suzuki M, Hibi T. Dietary histidine ameliorates murine colitis by inhibition of proinflammatory cytokine production from macrophages. Gastroenterology. 2009;136:564–74.PubMedCrossRef

18.

Bjerrum JT, Nielsen OH, Wang YL, Olsen J. Technology insight: metabonomics in gastroenterology-basic principles and potential clinical applications. Nat Clin Pract Gastroenterol Hepatol. 2008;5:332–43.PubMedCrossRef

19.

Hirayama A, Kami K, Sugimoto M, Sugawara M, Toki N, Onozuka H, Kinoshita T, Saito N, Ochiai A, Tomita M, Esumi H, Soga T. Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. Cancer Res. 2009;69:4918–25.PubMedCrossRef

20.

Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009;457:910–4.PubMedCrossRef

21.

Gao H, Lu Q, Liu X, Cong H, Zhao L, Wang H, Lin D. Application of 1H NMR-based metabonomics in the study of metabolic profiling of human hepatocellular carcinoma and liver cirrhosis. Cancer Sci. 2009;100:782–5.PubMedCrossRef

22.

Marion JF, Rubin PH, Present DH. Differential diagnosis of chronic ulcerative colitis and Crohn’s disease. In: Kirsner JB, editor. Inflammatory bowel disease. 5th ed. Philadelphia: WB Saunders; 2000. p. 315–25.

23.

Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ. 1989;298:82–6.PubMedCrossRef

24.

Myren J, Bouchier IA, Watkinson G, Softley A, Clamp SE, de Dombal FT. The O.M.G.E. multinational inflammatory bowel disease survey 1976–1982. A further report on 2,657 cases. Scand J Gastroenterol. 1984;19:1–27.

25.

Nishiumi S, Shinohara M, Ikeda A, Yoshie T, Hatano N, Kakuyama S, Mizuno S, Sanuki T, Kutsumi H, Fukusaki E, Azuma T, Takenawa T, Yoshida M. Serum metabolomics as a novel diagnostic approach for pancreatic cancer. Metabolomics. 2010;6:518–28.CrossRef

26.

Matts SG. The value of rectal biopsy in the diagnosis of ulcerative colitis. Q J Med. 1961;30:393–407.PubMed

27.

Shiomi Y, Nishiumi S, Ooi M, Hatano N, Shinohara M, Yoshie T, Kondo Y, Furumatsu K, Shiomi H, Kutsumi H, Azuma T, Yoshida M. A GCMS-based metabolomic study in mice with colitis induced by dextran sulfate sodium. Inflamm Bowel Dis 2011 (in press) doi:10.1002/ibd.21616.

28.

Fernández-Bañares F, Cabré E, González-Huix F, Gassull MA. Enteral nutrition as primary therapy in Crohn’s disease. Gut. 1994;35:55–9.CrossRef

29.

Lennie TA, McCarthy DO, Keesey RE. Body energy status and the metabolic response to acute inflammation. Am J Physiol. 1995;269:1024–31.

30.

Ling PR, Bistrian BR, Mendez B, Istfan NW. Effects of systemic infusions of endotoxin, tumor necrosis factor, and, interleukin-1 on glucose metabolism in the rat: relationship to endogenous glucose production and peripheral tissue glucose uptake. Metabolism. 1994;43:279–84.PubMedCrossRef

31.

Jijon HB, Churchill T, Malfair D, Wessler A, Jewell LD, Parsons HG, Madsen KL. Inhibition of poly(ADP-ribose) polymerase attenuates inflammation in a model of chronic colitis. Am J Physiol Gastointest Liver Physiol. 2000;279:641–51.

32.

Cetinkaya A, Bulbuloglu E, Kantarceken B, Ciralik H, Kurutas EB, Buyukbese MA, Gumusalan Y. Effects of l-carnitine on oxidant/antioxidant status in acetic acid-induced colitis. Dig Dis Sci. 2006;51:488–94.PubMedCrossRef

33.

Edwards FC, Truelove SC. The course and prognosis of ulcerative colitis. Gut. 1964;5:1–22.PubMedCrossRef

34.

Goh J, O’Morain CA. Nutrition and adult inflammatory bowel disease. Aliment Pharmacol Ther. 2003;17:307–20.PubMedCrossRef

35.

Rizzello F, Gionchetti P, Venturi A, Campieri M. Review article: medical treatment of severe ulcerative colitis. Aliment Pharmacol Ther. 2003;17:7–10.PubMedCrossRef

36.

Coëffier M, Déchelotte P. The role of glutamine in intensive care unit patients: mechanisms of action and clinical outcome. Nutr Rev. 2005;63:65–9.PubMedCrossRef

37.

Wu G, Morris SM Jr. Arginine metabolism: nitric oxide and beyond. Biochem J. 1998;336:1–17.PubMed

38.

Wu F, Dassopoulos T, Cope L, Maitra A, Brant SR, Harris ML, Bayless TM, Parmigiani G, Chakravarti S. Genome-wide gene expression differences in Crohn’s disease and ulcerative colitis from endoscopic pinch biopsies: insights into distinctive pathogenesis. Inflamm Bowel Dis. 2007;13:807–21.PubMedCrossRef

39.

Olsen J, Gerds TA, Seidelin JB, Csillag C, Bjerrum JT, Troelsen JT, Nielsen OH. Diagnosis of ulcerative colitis before onset of inflammation by multivariate modeling of genome-wide gene expression data. Inflamm Bowel Dis. 2009;15:1032–8.PubMedCrossRef

40.

Solem CA, Loftus EV Jr, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:707–12.PubMedCrossRef

41.

Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis. 2004;10:661–5.PubMedCrossRef

42.

Lennard-Jones JE, Lockhart-Mummery HE, Morson BC. Clinical and pathological differentiation of Crohn’s disease and proctocolitis. Gastroenterology. 1968;54:1162–70.PubMed

43.

Hoffenberg EJ, Fidanza S, Sauaia A. Serologic testing for inflammatory bowel disease. J Pediatr. 1999;134:447–52.PubMedCrossRef

44.

Peeters M, Joossens S, Vermeire S, Vlietinck R, Bossuyt X, Rutgeerts P. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol. 2001;96:730–4.PubMedCrossRef

45.

Dubinsky MC, Ofman JJ, Urman M, Targan SR, Seidman EG. Clinical utility of serodiagnostic testing in suspected pediatric inflammatory bowel disease. Am J Gastroenterol. 2001;96:758–65.PubMedCrossRef

46.

Sandborn WJ, Loftus EV Jr, Colombel JF, Fleming KA, Seibold F, Homburger HA, Sendid B, Chapman RW, Tremaine WJ, Kaul DK, Wallace J, Harmsen WS, Zinsmeister AR, Targan SR. Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn’s disease. Inflamm Bowel Dis. 2001;7:192–201.PubMedCrossRef

Titel: GC/MS-based profiling of amino acids and TCA cycle-related molecules in ulcerative colitis
verfasst von: Makoto Ooi
Shin Nishiumi
Tomoo Yoshie
Yuuki Shiomi
Michitaka Kohashi
Ken Fukunaga
Shiro Nakamura
Takayuki Matsumoto
Naoya Hatano
Masakazu Shinohara
Yasuhiro Irino
Tadaomi Takenawa
Takeshi Azuma
Masaru Yoshida
Publikationsdatum: 01.09.2011
Verlag: SP Birkhäuser Verlag Basel
Erschienen in: Inflammation Research / Ausgabe 9/2011
Print ISSN: 1023-3830
Elektronische ISSN: 1420-908X
DOI: https://doi.org/10.1007/s00011-011-0340-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

GC/MS-based profiling of amino acids and TCA cycle-related molecules in ulcerative colitis